Sinovac Vaccination and the Course of COVID-19 Disease in Hospitalized Patients in Turkey

Overview

Journal Ann Saudi Med

Specialty General Medicine

Date 2022 Jun 6

PMID 35658583

Authors

Leman Acun Delen

Mesut Ortekus

Affiliations

Soon will be listed here.

Abstract

Background: The Alpha variant of SARS-CoV-2 has a higher transmission rate than the first variant identified. The efficacy of vaccines is affected by the characteristics of SARS-CoV-2 variants.

Objective: Investigate the relationship of vaccination and virus variant on the course of the disease in patients who were hospitalized with a diagnosis of COVID-19.

Design: Retrospective, cohort study SETTING: Tertiary health institution PATIENTS AND METHODS: The study included patients older than the age of 18 years who were hospitalized in a COVID-19 service or the intensive care unit with a diagnosis of COVID-19 between 1 January 2021 and 30 April 2021. Demographic characteristics, vaccination and the Alpha virus variant status, comorbidities, and information about hospitalization were obtained from the hospital automation system and patient files.

Main Outcome Measures: Vaccination rate and relationship with course of disease.

Sample Size: 608 RESULTS: Most of the patients (n=482, 79.3%) were admitted to the COVID-19 service. More of the COVID-19 service patients had the Alpha variant than the patients admitted to ICU (<.009). The Alpha variant was also more common in younger patients (<.001). There was no relationship between the Alpha virus and comorbid diseases such as diabetes mellitus and hypertension. Mortality was lower in the patients who had received a second dose of the Sinovac vaccine (=.004) compared with unvaccinated patients.

Conclusion: Although the Alpha variant spreads faster, it has a milder course. If only the Sinovac vaccine is available, we recommend that the two doses of the Sinovac vaccine be administered.

Limitations: Our study is single-center and did not include pregnant and pediatric patients.

Conflict Of Interest: None.

Citing Articles

A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey.

Yilmaz D, Ustundag G, Buyukcam A, Sali E, Celik U, Avcu G Eur J Pediatr. 2023; 182(7):3231-3242.

PMID: 37140703 PMC: 10157577. DOI: 10.1007/s00431-023-04982-6.

References

Lorenzo-Redondo R, Nam H, Roberts S, Simons L, Jennings L, Qi C . A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways. EBioMedicine. 2020; 62:103112. PMC: 7655495. DOI: 10.1016/j.ebiom.2020.103112. View

Villoutreix B, Calvez V, Marcelin A, Khatib A . In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Int J Mol Sci. 2021; 22(4). PMC: 7915722. DOI: 10.3390/ijms22041695. View

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

Wang R, Hozumi Y, Yin C, Wei G . Mutations on COVID-19 diagnostic targets. Genomics. 2020; 112(6):5204-5213. PMC: 7502284. DOI: 10.1016/j.ygeno.2020.09.028. View

Naqvi A, Fatima K, Mohammad T, Fatima U, Singh I, Singh A . Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(10):165878. PMC: 7293463. DOI: 10.1016/j.bbadis.2020.165878. View

Velavan T, Meyer C . The COVID-19 epidemic. Trop Med Int Health. 2020; 25(3):278-280. PMC: 7169770. DOI: 10.1111/tmi.13383. View

Gupta R, Misra A . Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr. 2020; 14(3):251-254. PMC: 7102586. DOI: 10.1016/j.dsx.2020.03.012. View

Mishra S, Tripathi T . One year update on the COVID-19 pandemic: Where are we now?. Acta Trop. 2020; 214:105778. PMC: 7695590. DOI: 10.1016/j.actatropica.2020.105778. View

Groves D, Rowland-Jones S, Angyal A . The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. Biochem Biophys Res Commun. 2020; 538:104-107. PMC: 7643658. DOI: 10.1016/j.bbrc.2020.10.109. View

10.

Volz E, Mishra S, Chand M, Barrett J, Johnson R, Geidelberg L . Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021; 593(7858):266-269. DOI: 10.1038/s41586-021-03470-x. View

11.

Conti P, Caraffa A, Gallenga C, Kritas S, Frydas I, Younes A . The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. J Biol Regul Homeost Agents. 2020; 35(1):1-4. View

12.

Uddin M, Mustafa F, Rizvi T, Loney T, Al Suwaidi H, Al-Marzouqi A . SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses. 2020; 12(5). PMC: 7290442. DOI: 10.3390/v12050526. View

13.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

14.

Hodgson S, Mansatta K, Mallett G, Harris V, Emary K, Pollard A . What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2020; 21(2):e26-e35. PMC: 7837315. DOI: 10.1016/S1473-3099(20)30773-8. View

15.

Eaaswarkhanth M, Madhoun A, Al-Mulla F . Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?. Int J Infect Dis. 2020; 96:459-460. PMC: 7247990. DOI: 10.1016/j.ijid.2020.05.071. View

16.

Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W . Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-827.e19. PMC: 7332439. DOI: 10.1016/j.cell.2020.06.043. View

17.

Washington N, Gangavarapu K, Zeller M, Bolze A, Cirulli E, Schiabor Barrett K . Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell. 2021; 184(10):2587-2594.e7. PMC: 8009040. DOI: 10.1016/j.cell.2021.03.052. View

18.

Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N . The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020; 92(10):1915-1921. PMC: 7262275. DOI: 10.1002/jmv.25889. View

19.

Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y . Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7):1730-1741. DOI: 10.1111/all.14238. View

20.

Knoll M, Wonodi C . Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2020; 397(10269):72-74. PMC: 7832220. DOI: 10.1016/S0140-6736(20)32623-4. View